AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Friedreich's Ataxia

Recent research efforts aimed at curing Friedreich's Ataxia.

Last updated

Friedreich’s Ataxia

Overview

Friedreich’s ataxia (FA) is a rare inherited disorder in which changes in the FXN gene greatly reduce production of frataxin, a protein needed for healthy mitochondrial energy production. Most people have an expanded GAA DNA repeat in both copies of FXN. Symptoms commonly begin in childhood or adolescence and progressively affect balance, coordination, sensation, speech, strength, the heart, the spine, and sometimes blood-sugar control. The disease is life-limiting, although its course varies substantially between people. GeneReviews: Friedreich Ataxia (ncbi.nlm.nih.gov)

There is not yet a cure. Standard care combines multidisciplinary monitoring and treatment of neurologic, cardiac, orthopedic, diabetic, and rehabilitation needs. In the United States, omaveloxolone (Skyclarys) is approved for people aged 16 years and older; it can improve neurologic function in some patients but does not restore the defective FXN gene or replace lost cells. FDA: Skyclarys drug-trial snapshot (fda.gov)

Scope of Recent Research (2020–present)

Research activity has accelerated since 2020, shifting from treatments that reduce downstream stress in mitochondria toward approaches intended to address the core frataxin deficit: delivering a working FXN gene, increasing expression of the patient’s own silenced gene, supplying frataxin protein, or editing the disease-causing repeat. The field has reached early human proof-of-concept for cardiac gene replacement and for increasing endogenous frataxin, but no approach has yet shown that it can safely and durably correct both the neurological and cardiac disease throughout the body; therefore, a curative therapy remains investigational. Global research review (nature.com)

Major Breakthroughs and Emerging Therapies

Gene replacement. The most advanced potentially disease-modifying strategy uses adeno-associated virus (AAV), a modified viral delivery vehicle, to introduce a functional human FXN gene into cells. In 2026, pooled results from two open-label, dose-escalation studies of intravenous AAVrh.10hFXN/LX2006 gene therapy in 17 adults with FA cardiomyopathy found increased frataxin in heart biopsies, lower or stabilized left-ventricular mass in all participants, and lower troponin—a marker of heart-muscle injury—in most participants. These findings are promising for FA-related heart disease, but the trial was small, nonrandomized, and designed primarily to assess safety rather than to prove a cure. AAVrh.10hFXN clinical trial (jamanetwork.com)

A second AAV program, SGT-212 from Solid Biosciences, was designed to reach several key tissues through intravenous delivery plus direct delivery to the cerebellar dentate nuclei. Its supporting animal studies reported frataxin expression in heart, dorsal-root-ganglion, and cerebellar tissues, with improved survival and motor or cardiac measures in mouse models; these findings supported entry into a first-in-human Phase 1b study, but they are not yet evidence of benefit in people. SGT-212 preclinical package (solidbio.com)

Reactivating the patient’s own gene. DT-216P2 is a GeneTAC small molecule from Design Therapeutics that targets the expanded GAA repeat with the aim of reversing FXN gene silencing and increasing endogenous frataxin. In sponsor-reported, early Phase 1/2 data from 16 participants treated for four weeks, the highest-dose cohort showed increases in blood and muscle FXN measures alongside improvements in exploratory clinical measures. These results are encouraging because the treatment attempts to restore the patient’s natural frataxin production rather than add a replacement gene or protein; however, they are short-term, uncontrolled, and not yet peer-reviewed. RESTORE-FA four-week update (investors.designtx.com)

Frataxin replacement. Nomlabofusp (CTI-1601) is an injectable fusion protein engineered to enter cells and mitochondria, where it is processed into mature frataxin. In Phase 1 studies, it was generally well tolerated over the short treatment period and produced dose-related rises in frataxin measured in skin, cheek cells, and platelets. This establishes that replacement protein can reach peripheral tissues, but clinical efficacy and long-term safety remain unproven. Nomlabofusp Phase 1 study (pmc.ncbi.nlm.nih.gov)

Gene editing. Preclinical work is increasingly aimed at the repeat expansion itself. A 2020 study used patient-derived stem-cell models to create dorsal-root-ganglion organoids—three-dimensional cultures resembling the sensory nerve structures damaged in FA—and found that removal of FXN intron 1 rescued disease-related abnormalities, whereas removing only the expanded GAA tract did not fully do so. FXN editing in sensory-neuron organoids (nature.com) In 2025, researchers used base editors to introduce stabilizing interruptions into GAA repeats in patient cells and in an FA mouse model, reducing repeat expansion in treated nervous-system tissues. This is an important proof of principle, but it remains a laboratory and animal-model approach rather than a human therapy. Base editing of pathogenic repeats (nature.com)

Clinical Trials and Experimental Approaches

The strongest published clinical signal for a root-cause therapy is presently cardiac gene replacement. The AAVrh.10hFXN/LX2006 program, developed through Weill Cornell Medicine and Lexeo Therapeutics, evaluated two Phase 1/2-style dose-escalation studies registered as NCT05302271 and NCT05445323. In the 2026 pooled report, one possible vector-related myocarditis event occurred and resolved; three other serious adverse events were possibly related to prednisone immunosuppression. Larger controlled studies will be needed to determine whether the cardiac biomarker and imaging changes translate into fewer clinical events and longer survival. AAVrh.10hFXN clinical trial (jamanetwork.com)

Design Therapeutics’ open-label RESTORE-FA Phase 1/2 study of DT-216P2 is registered as NCT06874010. The company reported no serious adverse events or discontinuations in its initial four-week dataset, although transient liver-enzyme elevations occurred in several participants. Because the study is small, open-label, and short, the reported changes in modified Friedreich’s Ataxia Rating Scale (mFARS), balance, fatigue, and frataxin biomarkers should be treated as preliminary. RESTORE-FA four-week update (investors.designtx.com)

Other notable programs include Larimar Therapeutics’ ongoing open-label extension of Phase 2 nomlabofusp treatment, NCT06447025, and Solid Biosciences’ active first-in-human Phase 1b FALCON trial of SGT-212, NCT07180355. These studies are principally evaluating safety, dosing, biological activity, and feasibility; neither has established a cure or durable clinical efficacy. Nomlabofusp extension trial (clinicaltrials.gov) SGT-212 FALCON trial (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers combine human natural-history studies with disease-specific laboratory models. Patient-derived induced pluripotent stem cells are converted into sensory neurons and dorsal-root-ganglion organoids to test whether therapies correct frataxin deficiency, mitochondrial dysfunction, and neuronal survival in relevant human cell types. Mouse models with tissue-specific loss of frataxin are used to assess motor function, cardiac structure, survival, biodistribution, and dosing before human trials. FXN editing in sensory-neuron organoids (nature.com) SGT-212 preclinical package (solidbio.com)

Clinical development relies on biomarkers that can show whether a therapy reaches its target—such as frataxin RNA or protein, cardiac magnetic-resonance imaging, troponin, and mitochondrial measures—alongside functional outcomes such as mFARS. Longitudinal cohorts are especially important because FA progresses slowly and unevenly; the international FA Global Clinical Consortium’s UNIFAI natural-history program is intended to harmonize such data across sites and improve trial readiness. Natural-history study of FA (neurology.org) FA Global Clinical Consortium (curefa.org)

Leading Institutions and Funding

Key academic and clinical contributors include Weill Cornell Medicine, the University of Pennsylvania Gene Therapy Program, and the Broad Institute–associated base-editing research community, alongside specialist FA centers participating in international natural-history and interventional studies. Corporate developers include Lexeo Therapeutics, Solid Biosciences, Design Therapeutics, and Larimar Therapeutics. The recent AAVrh.10hFXN clinical report included support from the U.S. National Heart, Lung, and Blood Institute, reflecting the importance of federal investment in FA cardiomyopathy research. AAVrh.10hFXN clinical trial (jamanetwork.com) Base editing of pathogenic repeats (nature.com)

Patient-led funding is also central. The Friedreich’s Ataxia Research Alliance (FARA) supports basic, translational, and clinical work through grants that can reach $125,000 per year for general or cardiac awards, $200,000 per year for its translational-research award, and up to $250,000 per year for selected requests for proposals. FARA also helps organize the global clinical-research infrastructure needed for adequately powered trials in a rare disease. FARA grant program (curefa.org) FA Global Clinical Consortium (curefa.org)

Strengths, Limitations, and Challenges

The central strength of current research is that several strategies now act upstream of symptoms: gene replacement can supply FXN, GeneTAC therapy may reactivate endogenous FXN, protein replacement can supplement frataxin, and editing may eventually alter the unstable repeat itself. The 2026 AAVrh.10hFXN report provides early human evidence that frataxin delivery can affect the FA heart, while DT-216P2 provides an early signal that endogenous frataxin expression may be pharmacologically increased. AAVrh.10hFXN clinical trial (jamanetwork.com) RESTORE-FA four-week update (investors.designtx.com)

The major challenge is whole-body delivery at the right dose. FA damages difficult-to-reach tissues including the heart, dorsal root ganglia, spinal pathways, and cerebellum. AAV treatment can provoke immune reactions, may be difficult to redose, and requires careful control because too little frataxin may fail and excessive frataxin expression can be harmful in some models. Genome and base editing add concerns about editing unintended DNA sites and about long-term editor expression. Finally, most current clinical results are based on small, uncontrolled cohorts, so apparent improvements must be confirmed in longer, comparative trials with outcomes meaningful to patients. Gene-therapy and editing limitations review (pmc.ncbi.nlm.nih.gov) Base editing of pathogenic repeats (nature.com)

Outlook and Future Directions

As of October 16, 2026, FA is closer to root-cause treatment than it was at the start of the decade, but it is not yet close enough to call any intervention curative. The most important milestones to watch are durable follow-up from cardiac AAV gene-replacement studies; controlled trials testing whether cardiac and neurologic biomarker changes produce meaningful functional benefit; longer-term results for DT-216P2 and nomlabofusp; and evidence that next-generation vectors or editors can safely reach both nervous-system and cardiac targets. A genuine cure will likely need to show sustained restoration of frataxin across relevant tissues, prevention of further degeneration, acceptable long-term safety, and practical access for patients. Global research review (nature.com)

References

Don't see your disease? Request a report